Bio-Rad Laboratories Q2 Earnings Call Highlights

Impact · against what's priced in

Bio-Rad's results are mixed, with stagnant top-line growth and persistent academic market weakness offset by strong digital PCR growth and operational restructuring. While the stabilization of late-stage biopharma is a positive signal, the immediate headwind from China and the lagging recovery in government funding limit the upside.

BIO+0.10

No priced-in read yet

In context

Strong growth in digital PCR instruments (>20%) and a restructuring program targeting $30-$35 million in annual savings provide a positive offset to flat overall revenue and high-teen declines in China.

Read from the article alone

• life sciencesNew
• guidance
• earnings
• biotech
• BIO
• academic research
• china
• clinical diagnostics
• medical devices